Clinical Policy: Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro)

Reference Number: LA.PHAR.310
Effective Date: 07.01.22
Last Review Date: 06.02.2023~~8.22~~
Line of Business: Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Daratumumab (Darzalex®) is a CD38-directed cytolytic antibody. Daratumumab/hyaluronidase-fihj (Darzalex Faspro™) is a combination of daratumumab and hyaluronidase, an endoglycosidase.

FDA Approved Indication(s)

Darzalex and Darzalex Faspro are indicated for the treatment of adult patients with multiple myeloma (MM):

- In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory MM myeloma who have received at least one prior therapy
- In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for ASCT
- In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- As monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent
- In combination with carfilzomib and dexamethasone in patients with relapsed or refractory MM who have received one to three prior lines of therapy

Darzalex is additionally indicated for the treatment of adult patients with MM:

- In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a PI
- ~~In combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy~~

Darzalex Faspro is additionally indicated for the treatment of adult patients with:

- MM in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a PI.
- Light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed adult patients. This indication is approved under

accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Limitations of Use: Darzalex Faspro is not indicated and is not recommended for the treatment of patients with (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana HealthCare Connections® that Darzalex and Darzalex Faspro are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Multiple Myeloma (must meet all)**:**

1. Diagnosis of MM;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Darzalex or Darzalex Faspro is prescribed in one of the following ways (a or b):
   a. Primary therapy (i or ii):
      i. Ineligible for ASCT and in combination with one of the following (a or b):
         a) ~~In combination with~~ lenalidomide* and dexamethasone;
         b) ~~In combination with~~ bortezomib*, melphalan, and prednisone;
      ii. Eligible for ASCT in combination with one of the following (a,b,c, or d):
         a) bortezomib*, thalidomide*, and dexamethasone~~;~~;
         b) bortezomib*, lenalidomide*, and dexamethasone;
         c) bortezomib*, cyclophosphamide, dexamethasone;
         ~~c)~~d) carfilzomib*, lenalidomide*, and dexamethaose:
   b. Subsequent therapy (i.ii, or ii):
      i. In combination with dexamethasone and either lenalidomide*, bortezomib*(with or without cyclophosphamide), ~~or~~ carfilzomib*, or Xpovio* after ≥ 1 prior ~~therapy (off-label for Darzalex Faspro**)~~;
      ii. In combination with pomalidomide* and dexamethasone after ≥ 1 prior therapies including both of the following (a and b):
         a) An immunomodulatory agent (e.g., thalidomide*, lenalidomide*);
         ~~a)~~b) A PI (e.g., ixazomib*, bortezomib*, carfilzomib*);
      iii. As monotherapy after ≥ 3 prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent;

~~As monotherapy or in combination with pomalidomide* and dexamethasone after ≥ 2 prior therapies (off-label for Darzalex Faspro **), including both of the following (a and b):~~
~~an immunomodulatory agent (e.g. thalidomide*, lenalidomide*);~~
~~A PI (e.g., ixazomib*, bortezomib*, carfilzomib*);~~

**Prior authorization may be required.*
*~~** If request is for Darzalex Faspro, refer to NCCN for dosing regimen~~.*

5. Request meets one of the following (a or b):*
   a. Dose does not exceed the maximum indicated regimen in section V;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

B. Systemic Light Chain Amyloidosis (must meet all)**:**
1. Diagnosis of systemic light chain amyloidosis;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Member meets one of the following (a or b):
   a. Darzalex Faspro is prescribed in combination with bortezomib*, cyclophosphamide, and dexamethasone;
   b. Darzalex or Darzalex Faspro is prescribed for relapsed or refractory disease after ≥ 1 prior therapy (e.g., bortezomib*, lenalidomide*) (*off-label***);

   **Prior authorization may be required.*
   ***If request is for off-label use, refer to NCCN for dosing regimen.*
5. Dose is within FDA maximum limit for any FDA-approved indication in Section V or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

C. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. ~~1.~~If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53
3. ~~Refer to the off-label use policy for if diagnosis NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53 for Medicaid.~~

II. Continued Therapy

A. All Indications in Section I (must meet all)**:**
1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Darzalex of Darzalex Faspro for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose does not exceed the maximum indicated regimen in section V;

b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 2 above does not apply, refer to the off-label use policy LA.PMN.53

~~1. Currently receiving medication via Louisiana Healthcare Connections benefit and documentation supports positive response to therapy. Approval duration: Duration of request or 6 months (whichever is less); or~~

~~2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53 for Medicaid.~~

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy~~ies~~ – LA.PMN.53~~ for Medicaid or evidence of coverage documents.~~

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ASCT: autologous stem cell transplant
FDA: Food and Drug Administration
MM: multiple myeloma
NCCN: National Comprehensive Cancer Network
PI: proteasome inhibitor

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Agents with FDA-approved dosing for MM.		
Ninlaro® (ixazomib)	4 mg PO on days 1, 8, and 15 of every 28-day treatment cycle	See dosing regimen
bortezomib (Velcade®)	1.3 mg/m^2 SC or IV; frequency of administration varies based on specific use	
Kyprolis® (carfilzomib)	20 mg/m^2, 27 mg/m^2, and/or 56 mg/m^2 IV; frequency of administration varies based on specific use	
Revlimid® (lenalidomide)	10 mg or 25 mg PO QD; dose and frequency of administration vary based on specific use	

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Thalomid® (thalidomide)	100 mg, 200 mg, or 400 mg PO QD; dose and frequency of administration vary based on specific use	

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity
- Boxed warning(s): none reported

Appendix D: General Information

- The National Comprehensive Cancer Network compendium makes the following recommendation for Darzalex Faspro (category 2A): For multiple myeloma, may be used as a single agent or in combination with other systemic therapies where intravenous daratumumab is recommended.

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Darzalex	MM in combination with lenalidomide or pomalidomide (4-week cycle dosing regimens) and low-dose dexamethasone and for monotherapy	Weeks 1 to 8: 16 mg/kg IV weekly Weeks 9 to 24: 16 mg/kg IV every 2 weeks Weeks 25 onwards until disease progression: 16 mg/kg IV every 4 weeks	See dosing regimen - Package Insert, Table 1
	MM in combination with bortezomib, melphalan and prednisone ([VMP], 6-week cycle dosing regimen	Weeks 1 to 6: 16 mg/kg IV weekly Weeks 7 to 54: 16 mg/kg IV every 3 weeks Weeks 55 onwards until disease progression: 16 mg/kg IV every 4 weeks	See dosing regimen - Package Insert, Table 2
	MM in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen)	Induction Weeks 1 to 8: 16 mg/kg IV weekly Weeks 9 to 16: 16 mg/kg IV every 2 weeks	See dosing regimen - Package Insert, Table 3

Drug Name	Indication	Dosing Regimen	Maximum Dose
		Consolidation Weeks 1 to 8: 16 mg/kg IV every 2 weeks	
	MM in combination with bortezomib and dexamethasone (3-week cycle dosing regimen)	Weeks 1 to 9: 16 mg/kg IV weekly Weeks 10 to 24: 16 mg/kg IV every 3 weeks Weeks 25 onwards until disease progression: 16 mg/kg IV every 4 weeks	See dosing regimen - Package Insert, Table 4
	MM in combination with carfilzomib and dexamethasone (4-week cycle dosing regimen)	Week 1: 8 mg/kg IV days 1 and 2 Weeks 2 to 8: 16 mg/kg IV weekly Weeks 9 to 24: 16 mg/kg IV every 2 weeks Weeks 25 onwards until disease progression: 16 mg/kg IV every 4 weeks	See dosing regimen - Package Insert, Table 5
Darzalex Faspro	MM in combination with lenalidomide or pomalidomide and dexamethasone (4-week cycle) or as monotherapy	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes Weeks 1 to 8: weekly Weeks 9 to 24: every 2 weeks Weeks 25 onwards until disease progression: every 4 weeks	See dosing regimen - Package Insert, Table 1
	MM in combination with bortezomib, melphalan and prednisone ([VMP]; 6-week cycle)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes Weeks 1 to 6: weekly	See dosing regimen - Package Insert, Table 2

Drug Name	Indication	Dosing Regimen	Maximum Dose
		Weeks 7 to 54: every 3 weeks Weeks 55 onwards until disease progression: every 4 weeks	
	MM in combination with bortezomib, thalidomide, and dexamethasone ([D-VTd]; 4-week cycle)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes Induction: Weeks 1 to 8: weekly (total of 8 doses) Weeks 9 to 16: every 2 weeks (total of 4 doses) Consolidation: Weeks 1 to 8 (following ASCT): every 2 weeks (total of 4 doses)	See dosing regimen - Package Insert, Table 3
	MM in combination with bortezomib and dexamethasone ([D-Vd]; 3-week cycle)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes Weeks 1 to 9: weekly Weeks 10 to 24: every 3 weeks Weeks 25 onwards until disease progression: every 4 weeks	See dosing regimen - Package Insert, Table 4
Darzalex Faspro	Light Chain Amyloidosis – in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes Weeks 1 to 8: weekly (total of 8 doses) Weeks 9 to 24: every 2 weeks (total of 8 doses)	See dosing regimen - Package Insert, Table 5

Drug Name	Indication	Dosing Regimen	Maximum Dose
		Weeks 25 onwards until disease progression or a maximum of 2 years: every 4 weeks	

VI. Product Availability

Drug Name	Availability
Daratumumab (Darzalex)	Single-dose vial: 100 mg/5 mL, 400 mg/20 mL
Daratumumab/hyaluronidase-fihj (Darzalex Faspro)	Single-dose vial: providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase/15 mL

VII. References

1. Darzalex Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; March 202~~1~~2. Available at https://www.darzalex.com. Accessed ~~March 19~~April 28, 202~~1~~2~~1~~.
2. Darzalex FasPro Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; January 2022. Available at https://darzalexhcp.com. Accessed April 28~~March 19~~, 202~~1~~2~~1~~.
3. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed April 28~~March 19~~, 202~~1~~2.
4. National Comprehensive Cancer Network. Multiple Myeloma Version 5.202~~1~~2~~1~~. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed ~~March 19~~April 28, 202~~1~~2.
5. National Comprehensive Cancer Network Systemic Light Chain Amyloidosis Version ~~1~~2.202~~1~~2~~1~~. Available at https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf. Accessed April 28~~March 19~~, 202~~1~~2~~1~~.
6. Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. *Blood*. 2017; 130(7): 900-902.
7. Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. *Blood*. 2020;136(1):71-80. doi: 10.1182/blood.2019004460.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9144	Injection, daratumumab, 10mg and hyaluronidase-fihj
J9145	Injection, daratumumab, 10 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy	04.22	07.01.22
Per NCCN added additional combination regimens for MM primary therapy in those eligible for ASCT, for MM subsequent therapy added combination use with Xpovio and clarified use as monotherapy is allowable only after at least 3 prior lines of therapy or if double-refractory to PI and immunomodulatory agent. References reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section. Updated applicable HCPCS Codes.	06.02.23	

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise

professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.